Vanguard disaggregates holdings; reports 0 shares of Enanta (ENTA)
Rhea-AI Filing Summary
Enanta Pharmaceuticals Inc — The Vanguard Group filed an amended Schedule 13G reporting 0 shares beneficially owned of Common Stock, representing 0%, following an internal realignment.
The amendment states that on January 12, 2026 The Vanguard Group, Inc. reorganized and certain subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated ownership; no remaining beneficial stake in ENTA reported.
The amendment records 0 shares and 0% beneficial ownership as of the filing, attributing the change to an internal realignment on January 12, 2026. It cites SEC Release No. 34-39538 as the basis for separate reporting by subsidiaries.
Cash‑flow treatment and any prior holdings are not stated in the excerpt; subsequent filings would show if any subsidiary reports nonzero holdings. The practical impact depends on whether any Vanguard subsidiary now reports holdings separately.
FAQ
What does The Vanguard Group report for ENTA ownership?
Why did Vanguard change its reporting for ENTA?
Who signed the Schedule 13G/A for Vanguard?
Does the amendment identify any subsidiary holdings of ENTA?